How Much Does Zepbound Cost in Washington in 2026?

Zepbound Retail Price in Washington

The retail cash price for Zepbound at Washington pharmacies holds steady at Eli Lilly's national list price: $1,059 per month. That figure applies across all six dose strengths, from the 2.5 mg starter pen through the 15 mg maximum dose. Patients filling without insurance at chains like Costco, Walmart, or independent pharmacies in Seattle, Spokane, or Tacoma will see prices within a few dollars of that number.

This monthly cost reflects the wholesale acquisition cost (WAC) set by Eli Lilly, which has remained unchanged since the drug's FDA approval in November 2023 for chronic weight management. Washington state does not impose a separate drug pricing cap on GLP-1/GIP receptor agonists, so the retail figure mirrors the national average.

For context, the SURMOUNT-1 trial (N=2,539) demonstrated that tirzepatide 15 mg produced 22.5% mean body weight reduction at 72 weeks compared to 2.4% with placebo. The 10 mg dose achieved 21.4%, and the 5 mg dose reached 15.0%. These results represent the largest weight reductions seen in any phase 3 obesity trial to date, which partly explains why demand has outpaced supply since launch.

Sticker price alone does not tell the full story. Most Washington residents will pay significantly less through insurance, manufacturer programs, or compounded alternatives described in the sections below.

Insurance Coverage for Zepbound in Washington

Commercial insurance coverage for Zepbound in Washington varies by plan and employer. Large self-insured employers, state employee plans, and several major carriers in the state now include tirzepatide on their formularies, though most require prior authorization, a documented BMI threshold, and evidence of failed lifestyle modification.

According to Eli Lilly's 2024 payer coverage data, commercial coverage for anti-obesity medications has expanded significantly since 2023. However, individual plan details matter. A patient on Premera Blue Cross in Washington may face different step therapy requirements than someone on Regence or Aetna.

Typical prior authorization criteria in Washington commercial plans include:

• BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea)
• Documentation of at least 3 to 6 months of diet and exercise counseling
• No concurrent use of another GLP-1 receptor agonist
• Prescriber must be an MD, DO, NP, or PA

Patients whose commercial plans exclude weight management drugs still have options. The Eli Lilly savings card (discussed below) and compounded tirzepatide through 503A pharmacies both remain available in Washington state.

The Endocrine Society's 2024 clinical practice guideline recommends pharmacotherapy for patients with BMI ≥30 or BMI ≥27 with complications, calling tirzepatide a first-line option. This guideline language has helped clinicians write stronger prior authorization appeals.

Washington Medicaid Coverage for Zepbound

Washington Medicaid (Apple Health) covers Zepbound with prior authorization. This makes Washington one of a growing number of states where Medicaid beneficiaries can access tirzepatide for chronic weight management rather than only for type 2 diabetes.

The prior authorization process through the Washington Health Care Authority (HCA) requires the prescriber to submit clinical documentation demonstrating medical necessity. Standard requirements mirror commercial criteria: a qualifying BMI, documented comorbidities, and evidence that lifestyle interventions alone have been insufficient.

Processing times for Medicaid prior authorization in Washington typically run 3 to 5 business days for standard requests. Urgent requests may be expedited within 24 hours when clinically justified. Denials can be appealed through the HCA's fair hearing process.

One practical consideration: not all pharmacies in Washington participate in Apple Health networks. Patients should confirm their pharmacy accepts Medicaid before filling. The HCA maintains an online provider directory to verify pharmacy participation.

According to the CDC's National Health and Nutrition Examination Survey data, Washington's adult obesity prevalence stands at approximately 30%, affecting roughly 1.7 million adults. Medicaid coverage for anti-obesity medications has the potential to reach a substantial portion of this population that previously could not afford treatment.

The Eli Lilly Savings Card Program

Eli Lilly's savings card is the single most effective tool for reducing Zepbound's out-of-pocket cost in Washington. Commercially insured patients with a Zepbound-covering plan may pay as little as $25 per month. Patients whose commercial insurance does not cover Zepbound can use the card to pay a fixed cash price of $550 for a 1-month or $1,650 for a 3-month supply.

Key eligibility rules:

• Must have commercial (private) insurance. Medicare, Medicaid, Tricare, and other government-funded programs do not qualify.
• The card applies at participating pharmacies, which includes most major chains in Washington.
• The program has a maximum annual benefit cap. Once the cap is reached, the patient reverts to their plan's standard cost-sharing.

Patients should activate the card through Lilly's official portal before presenting it at the pharmacy. The card functions as a secondary payer, meaning the pharmacy first processes the primary insurance claim, then applies the savings card to reduce the remaining copay or coinsurance.

For Washington residents without any insurance coverage, the $550/month cash-pay option through the savings card still represents a 48% reduction from the $1,059 list price. This makes it one of the more accessible branded GLP-1/GIP agonist options available without a formulary listing.

Compounded Tirzepatide in Washington: Legality and Pricing

Compounded tirzepatide is legal and available in Washington through licensed 503A compounding pharmacies. These pharmacies operate under state Board of Pharmacy oversight and federal guidelines established by the FDA's Drug Quality and Security Act.

The average price for compounded tirzepatide in Washington runs approximately $249 per month, roughly 76% less than the branded Zepbound list price. Pricing varies by pharmacy, dose, and whether the patient uses a local brick-and-mortar compounder or a mail-order 503A pharmacy licensed to ship into Washington.

What patients should know about compounded tirzepatide:

Compounded medications are not FDA-approved products. They are prepared based on individual prescriptions using pharmaceutical-grade tirzepatide base. The FDA has stated that compounding fills a legitimate medical need when a patient cannot use the commercially available product (due to cost, allergy to an inactive ingredient, or need for a non-standard dose).

Washington's Board of Pharmacy requires 503A pharmacies to hold a valid state license and comply with USP 797 sterile compounding standards. Patients should verify their compounder's license through the Washington Department of Health's provider credential search.

Quality control is the primary concern. Branded Zepbound undergoes Lilly's standardized manufacturing and FDA lot-release testing. Compounded versions rely on the individual pharmacy's quality assurance processes. Patients choosing compounded tirzepatide should ask their pharmacy about third-party potency and sterility testing.

Dr. Robert Kushner, professor of medicine at Northwestern University Feinberg School of Medicine, has noted: "When patients cannot afford branded anti-obesity medications, compounded versions from reputable pharmacies can maintain treatment continuity, but patients should work closely with their prescriber to monitor dosing accuracy and clinical response."

Telehealth Prescribing of Zepbound in Washington

Washington state permits telehealth prescribing of Zepbound. No in-person visit is required before a clinician can write a tirzepatide prescription, provided the telehealth encounter meets the standard of care for an initial obesity evaluation.

Washington's telehealth parity law (RCW 48.43.735) requires insurers to cover telehealth-delivered services at the same rate as in-person visits when the service is clinically appropriate. This means both the consultation and the resulting Zepbound prescription should be reimbursable under the patient's plan.

Several telehealth platforms now serve Washington residents seeking GLP-1/GIP agonist prescriptions. A typical telehealth obesity visit includes a review of medical history, current medications, BMI calculation, discussion of weight-related comorbidities, and a treatment plan. Follow-up visits for dose titration are also conducted virtually.

Patients using telehealth should confirm two things before their appointment: that the prescriber is licensed in Washington state, and that the platform's clinicians can submit prior authorization paperwork if the patient's insurance requires it. Some direct-to-consumer platforms only write cash-pay prescriptions, which limits the patient's ability to use insurance benefits or the Lilly savings card.

How to Get the Lowest Price on Zepbound in Washington

Actual out-of-pocket cost depends on a patient's specific situation. Here is a decision framework for Washington residents seeking the lowest price.

If you have commercial insurance that covers Zepbound: Stack your plan's coverage with the Eli Lilly savings card. Expected cost: $25 per month at most pharmacies.

If you have commercial insurance that does not cover Zepbound: Use the Eli Lilly savings card at the $550/month cash-pay rate, or ask your prescriber to submit a prior authorization appeal citing the Endocrine Society guideline and SURMOUNT trial data.

If you have Washington Medicaid (Apple Health): Request prior authorization through your prescriber. Your out-of-pocket cost should be minimal once approved, typically $0 to $3 per fill.

If you are uninsured: Compare the Lilly savings card cash-pay price ($550/month) against compounded tirzepatide from a licensed Washington 503A pharmacy ($249/month average). The compounded option is cheaper but requires due diligence on pharmacy quality.

If you have Medicare: Neither the savings card nor Medicare Part D currently covers Zepbound for weight management. Compounded tirzepatide ($249/month) or patient assistance through Lilly's separate programs may be the most viable paths.

Dr. Fatima Cody Stanford, an obesity medicine physician at Massachusetts General Hospital, has stated: "Cost remains the single largest barrier to anti-obesity medication adherence. Patients who cannot maintain consistent access to their prescribed dose lose much of the weight they initially lost within 12 months of discontinuation."

This observation aligns with data from SURMOUNT-4, which showed that participants who discontinued tirzepatide after 36 weeks regained approximately two-thirds of their lost weight over the subsequent 52 weeks, compared to continued weight loss in those who stayed on treatment.

Dose Titration and Its Effect on Monthly Cost

Zepbound's prescribing information calls for a stepwise dose escalation: 2.5 mg weekly for 4 weeks, then 5 mg weekly. From there, the dose can increase in 2.5 mg increments every 4 weeks up to the 15 mg maximum, based on tolerability and clinical response.

Because Lilly prices all dose strengths identically at $1,059 per month, the titration schedule does not affect the sticker price. It does, however, affect insurance authorizations. Some Washington insurers authorize only 3 to 6 months initially, requiring reauthorization with documented weight loss (typically ≥5% from baseline) before approving continuation at higher doses.

Patients on compounded tirzepatide may see dose-dependent pricing. Some 503A pharmacies charge more for higher concentrations (10 mg and above) due to increased active ingredient costs. A patient stabilized on 5 mg compounded tirzepatide might pay $199/month, while the same patient at 15 mg could pay $349/month, depending on the pharmacy.

Comparing Zepbound to Other Weight-Loss Medications in Washington

Washington residents considering Zepbound should understand how it compares to alternatives on both efficacy and cost.

Wegovy (semaglutide 2.4 mg): List price approximately $1,349/month. The STEP-1 trial (N=1,961) showed 14.9% mean weight loss at 68 weeks versus 2.4% with placebo. Zepbound's dual GIP/GLP-1 mechanism produced greater weight loss in the SURMOUNT trials (up to 22.5% at 72 weeks with the 15 mg dose).

Contrave (naltrexone-bupropion): Generic versions available for approximately $50 to $100/month. Produces approximately 5 to 6% weight loss. An oral medication, which some patients prefer.

Phentermine: Available generically for approximately $15 to $30/month, but approved only for short-term use (up to 12 weeks per labeling). Washington prescribers commonly prescribe it off-label for longer durations.

Compounded semaglutide: Similar pricing to compounded tirzepatide ($199 to $399/month depending on dose and pharmacy), though tirzepatide has shown superior weight reduction in head-to-head comparisons.

The choice between branded Zepbound and alternatives should account for the patient's metabolic profile, insurance formulary, and budget. For patients with concurrent type 2 diabetes, tirzepatide's dual incretin mechanism offers both weight reduction and HbA1c lowering, which may consolidate two prescriptions into one.

Washington-Specific Pharmacy Tips

Fill at Costco. Costco pharmacies in Washington (locations in Seattle, Tacoma, Spokane, Kirkland, and others) consistently rank among the lowest-cost retail options for specialty medications, and a Costco membership is not required to use the pharmacy.

Use GoodRx or RxSaver for cash-price comparisons across Washington pharmacies before filling. Price variations of $20 to $50 exist between retailers in the same zip code.

For compounded tirzepatide, verify the pharmacy's Washington state license number through the Department of Health provider search. Ask whether the pharmacy performs third-party testing on each compounded batch and request a certificate of analysis.

Mail-order pharmacies licensed in Washington may offer lower prices than local brick-and-mortar options, particularly for 90-day fills. Confirm that the mail-order pharmacy is licensed to ship controlled and non-controlled injectable medications to Washington addresses.

Starting Zepbound at the 2.5 mg dose and titrating every 4 weeks as tolerated gives patients time to confirm insurance coverage and savings card activation before reaching maintenance doses where treatment interruption could trigger rebound weight gain.